{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T03:48:49Z","timestamp":1782445729703,"version":"3.54.5"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.bmcl.2022.128648","type":"journal-article","created":{"date-parts":[[2022,2,26]],"date-time":"2022-02-26T11:17:30Z","timestamp":1645874250000},"page":"128648","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Discovery and structure\u2013activity relationships of a novel oxazolidinone class of bacterial type II topoisomerase inhibitors"],"prefix":"10.1016","volume":"65","author":[{"given":"Amanda","family":"Lyons","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Kirkham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Blades","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Orr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Dauncey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Dick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rolf","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Bunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Finlayson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria J.","family":"Savage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Moyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley S.","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Newman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Ooi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Charrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Ratcliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil R.","family":"Stokes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Best","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Salisbury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Craighead","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian R.","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2022.128648_b0005","article-title":"Tackling Drug-Resistant Infections Globally: Final Report and Recommendations","author":"O\u2019Neill","year":"2016","journal-title":"HM Government."},{"issue":"8","key":"10.1016\/j.bmcl.2022.128648_b0010","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1086\/533452","article-title":"Federal Funding for the Study of Antimicrobial Resistance in Nosocomial Pathogens: No ESKAPE","volume":"197","author":"Rice","year":"2008","journal-title":"J Infect Dis."},{"issue":"8","key":"10.1016\/j.bmcl.2022.128648_b0015","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nrd4572","article-title":"ESKAPEing the labyrinth of antibacterial discovery","volume":"14","author":"Tommasi","year":"2015","journal-title":"Nat Rev Drug Discov."},{"issue":"2","key":"10.1016\/j.bmcl.2022.128648_b0020","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3201\/eid0702.010239","article-title":"Emerging mechanisms of fluoroquinolone resistance","volume":"7","author":"Hooper","year":"2001","journal-title":"Emerg Infect Dis."},{"issue":"1","key":"10.1016\/j.bmcl.2022.128648_b0025","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nrmicro3380","article-title":"Molecular mechanisms of antibiotic resistance","volume":"13","author":"Blair","year":"2015","journal-title":"Nat Rev Micro."},{"issue":"8","key":"10.1016\/j.bmcl.2022.128648_b0030","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.tim.2014.04.007","article-title":"Fluoroquinolone resistance: Mechanisms, impact on bacteria, and role in evolutionary success","volume":"22","author":"Redgrave","year":"2014","journal-title":"Trends Microbiol."},{"issue":"14","key":"10.1016\/j.bmcl.2022.128648_b0035","doi-asserted-by":"crossref","first-page":"4055","DOI":"10.1039\/c0cc05111j","article-title":"Molecular mechanisms of antibiotic resistance","volume":"47","author":"Wright","year":"2011","journal-title":"Chem Commun."},{"issue":"4","key":"10.1016\/j.bmcl.2022.128648_b0040","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1021\/acsinfecdis.8b00315","article-title":"Mechanistic and Structural Basis for the Actions of the Antibacterial Gepotidacin against Staphylococcus aureus Gyrase","volume":"5","author":"Gibson","year":"2019","journal-title":"ACS Infect Dis."},{"issue":"11","key":"10.1016\/j.bmcl.2022.128648_b0045","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1021\/acs.jmedchem.9b01738","article-title":"Two Decades of Successful SAR-Grounded Stories of the Novel Bacterial Topoisomerase Inhibitors (NBTIs)","volume":"63","author":"Kolari\u010d","year":"2020","journal-title":"J Med Chem."},{"issue":"15","key":"10.1016\/j.bmcl.2022.128648_b0050","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1016\/j.bmcl.2017.06.009","article-title":"Novel 3-fluoro-6-methoxyquinoline derivatives as inhibitors of bacterial DNA gyrase and topoisomerase IV","volume":"27","author":"Mitton-Fry","year":"2017","journal-title":"Bioorganic Med Chem Lett."},{"key":"10.1016\/j.bmcl.2022.128648_b0055","doi-asserted-by":"crossref","first-page":"112324","DOI":"10.1016\/j.ejmech.2020.112324","article-title":"Novel bacterial topoisomerase inhibitors derived from isomannide","volume":"199","author":"Okumu","year":"2020","journal-title":"Eur J Med Chem."},{"issue":"12","key":"10.1016\/j.bmcl.2022.128648_b0060","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1016\/j.bmcl.2015.04.063","article-title":"Hydroxy tricyclic 1,5-naphthyridinone oxabicyclooctane-linked novel bacterial topoisomerase inhibitors as broad-spectrum antibacterial agents-SAR of RHS moiety (Part-3)","volume":"25","author":"Singh","year":"2015","journal-title":"Bioorg Med Chem Lett."},{"issue":"5","key":"10.1016\/j.bmcl.2022.128648_b0065","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02100-16","article-title":"Novel Bacterial Topoisomerase Inhibitors with Potent Broad-Spectrum Activity against Drug-Resistant Bacteria","volume":"61","author":"Charrier","year":"2017","journal-title":"Antimicrob Agents Chemother."},{"issue":"7309","key":"10.1016\/j.bmcl.2022.128648_b0070","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/nature09197","article-title":"Type IIA topoisomerase inhibition by a new class of antibacterial agents","volume":"466","author":"Bax","year":"2010","journal-title":"Nature"},{"issue":"17","key":"10.1016\/j.bmcl.2022.128648_b0075","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1016\/j.bmcl.2016.07.061","article-title":"Discovery and structure\u2013activity relationships of a novel isothiazolone class of bacterial type II topoisomerase inhibitors","volume":"26","author":"Cooper","year":"2016","journal-title":"Bioorg Med Chem Lett."},{"issue":"3","key":"10.1016\/j.bmcl.2022.128648_b0080","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1128\/AAC.02820-15","article-title":"In vitro activity of gepotidacin, a novel triazaacenaphthylene bacterial topoisomerase inhibitor, against a broad spectrum of bacterial pathogens","volume":"60","author":"Biedenbach","year":"2016","journal-title":"Antimicrob Agents Chemother."},{"issue":"9","key":"10.1016\/j.bmcl.2022.128648_b0085","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00207-19","article-title":"Rapid Evolution of Reduced Susceptibility against a Balanced Dual-Targeting Antibiotic through Stepping-Stone Mutations","volume":"63","author":"Szili","year":"2019","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.bmcl.2022.128648_b0090","doi-asserted-by":"crossref","unstructured":"Taylor SN, Morris DH, Avery AK, et al. Gepotidacin for the Treatment of Uncomplicated Urogenital Gonorrhea: A Phase 2, Randomized, Dose-Ranging, Single-Oral Dose Evaluation. Clin Infect Dis. 2018;67(4):504-512. doi:10.1093\/cid\/ciy145.","DOI":"10.1093\/cid\/ciy145"},{"key":"10.1016\/j.bmcl.2022.128648_b0095","doi-asserted-by":"crossref","first-page":"104266","DOI":"10.1016\/j.bioorg.2020.104266","article-title":"Recent advancements in the medicinal chemistry of bacterial type II topoisomerase inhibitors","volume":"104","author":"Jaswal","year":"2020","journal-title":"Bioorg Chem."},{"issue":"17","key":"10.1016\/j.bmcl.2022.128648_b0100","doi-asserted-by":"crossref","first-page":"5029","DOI":"10.1021\/jm060379l","article-title":"Medicinal Chemistry of hERG Optimizations: Highlights and Hang-Ups","volume":"49","author":"Jamieson","year":"2006","journal-title":"J Med Chem."},{"issue":"15","key":"10.1016\/j.bmcl.2022.128648_b0105","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1021\/jm300690s","article-title":"Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II with reduced p K a: Antibacterial agents with an improved safety profile","volume":"55","author":"Reck","year":"2012","journal-title":"J Med Chem."},{"key":"10.1016\/j.bmcl.2022.128648_b0110","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.3389\/fphar.2019.01572","article-title":"An Update on the Structure of hERG","volume":"10","author":"Butler","year":"2020","journal-title":"Front Pharmacol."},{"issue":"3","key":"10.1016\/j.bmcl.2022.128648_b0115","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1152\/physrev.00036.2011","article-title":"hERG K+ Channels: Structure, Function, and Clinical Significance","volume":"92","author":"Vandenberg","year":"2012","journal-title":"Physiol Rev."},{"issue":"5","key":"10.1016\/j.bmcl.2022.128648_b0120","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/jcc.540150503","article-title":"ICM - A new method for protein modeling and design: Applications to docking and structure prediction from the distorted native conformation","volume":"15","author":"Abagyan","year":"1994","journal-title":"J Comput Chem."},{"issue":"5","key":"10.1016\/j.bmcl.2022.128648_b0125","doi-asserted-by":"crossref","first-page":"e02385","DOI":"10.1128\/AAC.02385-16","article-title":"A Phase I, Randomized, Double-Blinded, Placebo- and Moxifloxacin-Controlled, Four-Period Crossover Study To Evaluate the Effect of Gepotidacin on Cardiac Conduction as Assessed by 12-Lead Electrocardiogram in Healthy Volunteers","volume":"61","author":"Hossain","year":"2017","journal-title":"Antimicrob Agents Chemother."},{"key":"10.1016\/j.bmcl.2022.128648_b0130","unstructured":"WO\/2017\/137744."}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X2200124X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X2200124X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:45:08Z","timestamp":1760773508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X2200124X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":26,"alternative-id":["S0960894X2200124X"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.128648","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery and structure\u2013activity relationships of a novel oxazolidinone class of bacterial type II topoisomerase inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2022.128648","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"128648"}}